Profile for VistaGen Therapeutics Inc. (VTGN)

$ 0.435   0.0048 (+1.12%) Volume: 144.16k 4:00 PM EST Dec 6, 2019
Business Description:
VistaGen Therapeutics Inc is a clinical-stage biopharmaceutical company that develops and commercializes product candidates for patients with central nervous system diseases. Its product AV-101 is currently being evaluated in a Phase 2 monotherapy study.
Address: 343 Allerton Avenue, South San Francisco, San Francisco, CA, USA, 94080
Telephone: +1 650 577-3600 Website: https://www.vistagen.com
Facsimile: +1 888 482-2602 Email: [email protected]
Details
CEO: Shawn K. Singh
Employees: 9 Market Cap: 18.8m
Issue Type: CS
Auditor: OUM & Co. LLP
Last Audit: Unqualified Opinion with Explanation
Indices: Biotechnology
Industry Classifications
Sector: Healthcare CIK: 1411685
Industry: Biotechnology
Sub-Industry:    Biotechnology
NAICS: Pharmaceutical Preparation Manufacturing (325412)
SIC: Pharmaceutical Preparations (2834)